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Abstract
 
A functional hybrid receptor associating the common 
 
 
 
 chain (
 
 
 
c) with the granulocyte/mac-
rophage colony-stimulating factor receptor 
 
  
 
(GM-CSFR
 
 
 
) chain is found in mobilized hu-
man peripheral blood (MPB) CD34
 
 
 
 hematopoietic progenitors, SCF/Flt3-L primed cord
blood (CB) precursors (CB
 
Pr
 
 CD34
 
 
 
/CD56
 
 
 
), and CD34
 
 
 
 myeloid cell lines, but not in nor-
mal natural killer (NK) cells, the cytolytic NK-L cell line or nonhematopoietic cells. We dem-
onstrated, using CD34
 
 
 
 TF1
 
 
 
 cells, which express an interleukin (IL)-15R
 
 
 
/
 
 
 
/
 
 
 
c receptor,
that within the hybrid receptor, the GM-CSFR
 
 
 
 chain inhibits the IL-15–triggered 
 
 
 
c/JAK3-
specific signaling controlling TF1
 
 
 
 cell proliferation. However, the 
 
 
 
c chain is part of a func-
tional GM-CSFR, activating GM-CSF–dependent STAT5 nuclear translocation and the pro-
liferation of TF1
 
 
 
 cells. The hybrid receptor is functional in normal hematopoietic progenitors
in which both subunits control STAT5 activation. Finally, the parental TF1 cell line, which
lacks the IL-15R
 
 
 
 chain, nevertheless expresses both a functional hybrid receptor that controls
JAK3 phosphorylation and a novel IL-15
 
 
 
/
 
 
 
c/TRAF2 complex that triggers nuclear factor 
 
 
 
B
activation. The lineage-dependent distribution and function of these receptors suggest that they
are involved in hematopoiesis because they modify transduction pathways that play a major
role in the differentiation of hematopoietic progenitors.
Key words: IL-15 • GM-CSF • IL-15R • signal transduction • CD34
 
 
 
 cells
 
Introduction
 
The development of hematopoietic cells is controlled by
hematopoietic growth factors, cytokines and chemokines
produced in the bone marrow (BM)
 
*
 
 by accessory cells and
T lymphocytes (1, 2), and by several other mechanisms (3).
Hematopoietic factors constitute a complex network, in
which each cytokine may act at various stages: for example,
myeloid growth factors such as G-CSF and GM-CSF may
also affect the lymphoid compartment (4, 5). GM-CSF in-
hibits the expansion of the NK cell progenitor population
from unprimed BM CD34
 
 
 
 cells, and the generation and
functioning of NK cells both in vivo and in vitro (5, 6).
IL-15, the most powerful factor inducing the differen-
tiation of CD34
 
 
 
 hematopoietic progenitor cells into
CD56
 
 
 
/CD3
 
 
 
 NK cells in vivo (7), may also cause a large
increase in the number of long-term culture-initiating cells
(LTC-IC) when added to the IL-3/SCF/Flt3-L combina-
 
Address correspondence to Dr. Bruno Azzarone, INSERM U542, Bâti-
ment Lavoisier, Hôpital Paul Brousse, 94807 Villejuif, France. Phone: 00-
33-145595344; Fax: 00-33-145595343; E-mail: bazzarone@hotmail.com
 
*
 
Abbreviations used in this paper:
 
 BM, bone marrow; CB, cord blood;
MPB, mobilized peripheral blood.T
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tion (8). Transgenic mice carrying a mutation in the cyto-
plasmic domain of the common gamma chain (
 
 
 
c), or lack-
ing the signaling kinase JAK3, both of which are necessary
for IL-15–mediated signaling, have very low lymphocyte
counts and display dysregulated myelopoiesis (9, 10).
Moreover, the erythroid burst-forming cells of these mice
have a larger than normal fraction of hematopoietic precur-
sors with the CD34
 
 
 
/
 
 
 
c
 
 
 
 phenotype (11). These data sug-
gest that there is cross talk between myeloid growth factors
and IL-15, which may regulate the balance between the
myeloid and lymphoid lineages during hematopoietic dif-
ferentiation. This regulation may operate at the level of sig-
nal transduction because IL-15 and GM-CSF share signal-
ing pathways (JAK2/STAT5 and NF-
 
 
 
B) heavily involved
in the control of hematopoiesis (12–16). Alternatively, the
cross talk between these two cytokines may involve direct
interactions between their receptor subunits, as suggested
by the fact that GM-CSF almost totally inhibits IL-2 bind-
ing to IL-2/IL-15R
 
 
 
/
 
 
 
c in the M07sb CD34
 
 
 
 hemato-
poietic cell line (17). We investigated whether this cross
talk resulted from a physical interaction between the two
receptors, possibly involving the 
 
 
 
c chain and the GM-CS-
FR
 
 
 
 chain. Indeed, these two subunits identify two fami-
lies of cytokines, one with the 
 
 
 
c chain (IL-2, IL-4, IL-7,
IL-9, IL-13, IL-15, and IL-21; references 7 and 18) and the
other, with the GM-CSFR
 
 
 
 chain (IL-3, IL-5, and GM-
CSF; reference 19).
In this study, we demonstrate that normal CD34
 
 
 
 cells,
but not nonhematopoietic cells, express a novel functional
hybrid receptor composed of the 
 
 
 
c and GM-CSFR
 
 
 
chains, in which the GM-CSFR
 
 
 
 chain may inhibit 
 
 
 
c/
JAK3 signaling. This complex is maintained in CD34
 
 
 
 my-
eloid and cord blood (CB)
 
Pr
 
 CD34
 
 
 
/CD56
 
 
 
 cells, but not
in mature NK cells, suggesting that it is involved in con-
trolling hematopoietic differentiation.
 
Materials and Methods
 
Purification of CD34
 
 
 
 Cells.
 
Mononuclear cells from CB or
adult G-CSF mobilized peripheral blood (MPB) were isolated by
centrifugation on a Ficoll gradient (Lymphoprep Nicomed
Pharma SA). Adherent cells were isolated by adhesion to plastic
Petri dishes for 2 h at 37
 
 
 
C. CD34
 
 
 
 cells were selected by an im-
munomagnetic method (Miltenyi Biotec), on nonadherent
mononuclear cells labeled with a mAb specific for the QBEND10
epitope of the CD34 antigen, achieving a purity 
 
 
 
97%, as previ-
ously described (20). CB CD34
 
 
 
 cells were used unprimed or af-
ter treatment with SCF/Flt3-L to expand the population of
CD34
 
 
 
/CD56
 
 
 
 primed progenitors (CB
 
Pr
 
) in which the fre-
quency of NK cell precursors may be 65 to 235 times higher than
that in freshly prepared CD34
 
 
 
 HPCs (7).
 
Isolation and Culture of Normal Polyclonal NK Cells.
 
Non-
adherent PBMCs from healthy volunteers were isolated by cen-
trifugation on a Ficoll gradient. CD3
 
 
 
/CD4
 
 
 
/CD8
 
 
 
 
 
cells were
purified by negative depletion and cultured with 100 U/ml rIL-2
(Proleukin; Chiron Corp.) in the presence of 10
 
5
 
 irradiated allo-
genic PBMCs/well and 10
 
4
 
 221 lymphoblastoid cells/well. By
day 15, almost all the proliferating cells expressed CD16 and
CD56 antigens.
 
Cell Lines.
 
Human TF1
 
 
 
 (IL-15R
 
 
 
/
 
 
 
/
 
 
 
c) and M07sb (IL-
15R
 
 
 
/
 
 
 
c) are two IL-15–dependent leukemic cell lines, whereas
TF1 (IL-15R
 
 
 
/
 
 
 
c) is a GM-CSF–dependent cell line. TF1 and
TF1
 
 
 
 cells have the potential to display proerythroid differentia-
tion whereas M07Sb cells display promegakaryocytic differentia-
tion. NK-L is a functional human cytolytic NK cell line that is
dependent on rIL-2. Raji is a B cell line (IL-15R
 
 
 
/
 
 
 
c) that does
not depend on growth factors for its proliferation. The growth
characteristics and phenotypes of these cells have been reported
elsewhere (21–25). Cells were maintained in RPMI medium
(Eurobio) supplemented with 10% FCS (ATGC Biotechnologie),
2 mM glutamine, 1% antibiotics (GIBCO BRL), 10 ng/ml rIL-
15, or rGM-CSF (R&D Systems) at 37
 
 
 
C, under an atmosphere
of 5% CO
 
2
 
/95% air. Cells were subcultured twice per week by
seeding fresh culture medium with 10
 
5
 
 cells/ml. The human stro-
mal fibroblast MS9 strain, isolated in culture from the spleen of a
patient with a myeloproliferative syndrome, was used as a feeder
layer for hematopoietic cells. MS9 fibroblasts express a bioactive
membrane-bound IL-15 that induces the NK cell differentiation
of CD34
 
 
 
 cells; they also secrete GM-CSF (26, 27). MS9 cells
between passages 5 and 10 were cultured for 72 h at a density of
2 
 
 
 
 10
 
5
 
 cells/ml in RPMI medium supplemented with 10% FCS
in 6-well plates before being brought into contact with hemato-
poietic cells (5 
 
 
 
 10
 
5 cells/well). TF1  and NK-L cells were
kindly provided by Drs. Paul Sondel (Dept. of Human Oncology,
University of Wisconsin, Madison, WI) and Alessandro Moretta
(Department of Experimental Medicine, University of Genoa,
Genoa, Italy), respectively.
Proliferation Assays. TF1  cells and Raji cells (3   105 cells/
ml) were cultured for 4 d in complete growth medium supple-
mented with rIL-15 or rGM-CSF (10 ng/ml). Sister cultures
were treated with neutralizing anti–IL-15R  M162 (developed
by Immunex Corp., provided by Genmab A/S, Copenhagen,
Denmark), rat anti- c (TUGh4), and anti-GM-CSFR  (BD
Biosciences/Becton Dickinson) mAbs.
TF1  cells (3   105 cells/ml) were also cultured for 4 d with
MS9 stromal cells as the feeder layer. Sister cultures were treated
with anti–IL-15 (R&D Systems), anti–IL-15R  M162, anti–IL-
15R  (CF-1; a gift from Dr. Y. Jacques, U463 INSERM, Nantes,
France), anti- c (TUGh4), anti-GM-CSFR , or anti-GM-CS-
FR  (S-20; Santa Cruz Biotechnology, Inc.) mAbs. In some inhi-
bition experiments, we used low concentrations of anti–IL-15R 
and anti- c mAbs, because a combination of 1  g/ml of each
mAb is more efficient than a single dose of 10  g/ml of each mAb
at inhibiting IL-15 effects (23). Cells were counted in triplicate.
The statistical significance of differences was determined using
Student’s t test, with P   0.05 considered significant.
Analysis of IL-15 Signal Transduction in the Human Hematopoietic
TF1  Cell Line and in CBPr CD34 /CD56  Precursors. For sig-
nal transduction analysis, cells were incubated overnight with a
low concentration of rIL-15 (0.5 ng/ml) and were then deprived
of growth factors for 3 h at 37 C. Cells were then stimulated by
incubation with 10 ng/ml rIL-15 for 5 to 15 min. In some exper-
iments, cells were initially treated for 1 h with either 10  g/ml
neutralizing antibody against IL-15, IL-15R ,  c, or GM-CS-
FR  chains or with the JAK3-specific inhibitor, WHI-P131
(Calbiochem), which has no effect on JAK1 and JAK2.
Immunoblotting: Western Blotting. Experiments were per-
formed as described previously (12, 14, 28, 29). Briefly, cultures
were serum-starved to reduce basal phosphorylation levels. Cells
were then washed twice and suspended in lysis buffer supple-
mented with 0.5% NP-40. For immunoprecipitation, lysates
were incubated with anti- c (TUGh4), anti-JAK3 (Upstate Bio-T
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technology) or polyclonal anti-TRAF2 (Santa Cruz Biotech-
nology, Inc.) antibody and immune complexes were captured by
incubation with protein G-Sepharose beads (Amersham Bio-
sciences) overnight at 4 C. The captured immune complexes
were washed twice with lysis buffer. Complexes or lysates (for
Western blotting) were then dissolved in Laemmli buffer, boiled,
and separated by SDS-PAGE (7.5% or 12% polyacrylamide gels).
The protein bands were transferred to PVDF membranes (NEN
Life Science Products). Membranes were blocked by incubation
with 5% BSA and probed with the following antibodies: anti-
JAK1, anti-JAK2, and 4G10 anti-phosphotyrosine (Upstate Bio-
technology/USA Euromodex), anti-pJAK1 (Tyr 1022/1023),
anti-pJAK2 (Tyr 1007/Tyr 1008), anti-STAT3, anti-pSTAT3
(Tyr705), and anti-STAT6 (Santa Cruz Biotechnology, Inc.),
anti-STAT5 (Transduction Laboratories/Becton Dickinson),
anti-pSTAT5 (Tyr694), anti-pSTAT6 (Tyr641; Cell Signaling/
New England Biolabs, Inc.) and anti-pI B  (Calbiochem).
Primary antibody binding to the membrane was detected by
incubation with peroxidase-conjugated secondary antibodies, fol-
lowed by the enhanced chemiluminescence (ECL) system (Am-
ersham Biosciences). The membrane was then subjected to densi-
tometry, including correction for background, with analysis using
NIH Image software. To correct for possible variations in the
amount of protein loaded, values are expressed as pSTAT/STAT
ratios. Results are expressed as increases (e.g., three times) with
respect to the results obtained for untreated cells.
Confocal Microscopy. For the double staining of  c and GM-
CSFR  chains, human MPB and CB CD34  cells, the leukemic
cell lines (TF1, TF1 , and M07sb), and MS9 cells were washed
and permeabilized by incubation with ORTHOpermeafix
(Ortho Diagnostic Systems Inc.) for 45 min at room temperature.
Cells were then stained with anti- c (TUGh4) mAb and with the
biotinylated anti–GM-CSFR  secondary mAb, and were then
incubated at room temperature with Alexa Fluor594-GAR and
streptavidin-Alexa Fluor594 (Molecular Probes). The extent of
association between the two chains was assessed using the colo-
calization option of Methamorphe Software (Universal Imagine).
We also used confocal microscopy to evaluate production of the
activated transcription factor, pSTAT5, in TF1  and M07sb cells.
Cells were starved of growth factors overnight and were then
stimulated with rGM-CSF, as described above. Some samples
were pretreated with anti–IL-15 / c or anti–GM-CSFR 
mAbs. Cells were then permeabilized and indirect immunofluo-
rescence assessed by means of antibodies recognizing the phos-
phorylated form of the transcription factor STAT5 (pSTAT5).
Samples were washed and incubated with Alexa Fluor488-GARa
antibody. Nuclei were stained with 2  g/ml propidium iodide
(PI, red staining). All antibodies were dissolved in PBS supple-
mented with 10 mg/ml BSA to block nonspecific binding. The
stained cells were washed with PBS, centrifuged in a Cytospin 3
(Shandon) onto glass slides, and mounted under a coverslip in
Prolong Antifade (Molecular Probes) mounting medium. The
slides were analyzed by laser scanning confocal microscopy, using
a Leica TCS Confocal System.
Results
Human Hematopoietic CD34  Cells Express a Hybrid  c/
GM-CSFR  Receptor. We investigated the possible inter-
actions between IL-15R and GM-CSFR complexes in hu-
man hematopoietic and nonhematopoietic cells by Western
blotting (Fig. 1 A), coimmunoprecipitation (Fig. 1 B), and
confocal microscopy (Fig. 1 C). The Western blotting of
total lysates (Fig. 1 A) showed that the cells analyzed
(TF1 , M07Sb, and MPB CD34 ) expressed both the  c
chain (a single band of 64 kD) and the GM-CSFR  chain
(a major band of 130 kD, corresponding to the mature pro-
tein, and a second band of  95 kD, corresponding to the
nonglycosylated precursor protein; reference 30).
Human MPB CD34  cells, CBPr CD34 /CD56  pro-
genitors and normal polyclonal NK cells were immunopre-
cipitated with anti- c mAb, and the  c membranes were
reprobed with mAbs recognizing the  c and GM-CSFR 
chains. Reprobing with the anti- c mAb confirmed the
presence of a specific 64 kD band, whereas reprobing with
anti–GM-CSFR  mAb resulted in detection of the specific
130 kD band in MPB CD34  and CBPr CD34 /CD56 
cells, but not in polyclonal NK cells from normal donors
(Fig. 1 B, panel a). Thus, normal human CD34  cells ex-
press a  c/GM-CSFR  complex, which is not detectable
in mature NK cells.
The  c/GM-CSFR  association was also detected both
in the proerythroid TF1 and TF1  cell lines, which ex-
pressed IL-15R / c and IL-15R / / c, respectively, and
in the promegakaryocytic (M07sb) cells expressing IL-
15R / c, whereas it was not detected in the cytolytic
NK-L cell line (Fig. 1 B, panel b). In addition, the  c/
GM-CSFR  complex was not found in human skin myo-
fibroblasts despite the presence of the  c and GM-CSFR 
chains in these cells (Fig. 1 B, panel c). Reprobing the  c
membrane with anti-GM-CSFR  or anti-gp130 mAbs did
not give a specific signal (unpublished data).
We demonstrated, by confocal microscopy, the colocal-
ization of the  c (green staining) and GM-CSFR  (red
staining) chains in MPB and CB CD34  progenitors, as
well as in the TF1, TF1  and M07sb cell lines (Fig. 1 C).
The images presented are overlay-compacted images from
confocal analysis of 1  m serial optical sections from the
cell surface to the inner compartment.
In MPB CD34  and unprimed CB CD34  cells (Fig. 1
C, panels a1 and a2), all cells displayed strong colocalization
of the two molecules (yellow staining), restricted to the
membrane/submembrane compartment. In TF1 and TF1 
cells (Fig. 1 C, panels b1 and b2), we observed similar yel-
low staining of the membrane/submembrane compartment
and spotted yellow staining in the cytoplasm, suggesting
that the hybrid receptor was taken up by some of the cells.
This punctate distribution of the  c/GM-CSFR  complex
in the cytoplasms was the predominant staining pattern in
M07sb cells (Fig. 1 C, panel b3). No colocalization was ob-
served in human MS9 myofibroblasts (Fig. 1 C, panel c).
The specificity of  c and GM-CSFR  chain colocalization
was further confirmed by the lack of colocalization of the
 c chain and the IL-6R subunit gp130 (Fig. 1 C, panel d)
or the  1 integrin (Fig. 1 C, panel e) in normal CB CD34 
cells. Computerized quantification of the extent to which
the  c chain and the GM-CSFR  chain were colocalized
in normal and leukemic CD34  cells showed that 74.9%
(MPB CD34 ), 66.3% (TF1 ), 50.2% (TF1), and 58.3%
(M07sb) of the GM-CSFR  chain colocalized with the  cT
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chain, whereas 94.1% (MPB CD34 ), 99.6% (TF1 ),
82.1% (TF1), and 93.6% (M07sb) of the  c chain colocal-
ized with the GM-CSFR  chain. Our results indicate that
the  c chain is almost completely associated with the GM-
CSFR  chain, with  30–40% of the GM-CSFR  chain
left free.
The expression of this hybrid receptor is constitutive
and does not seem to be influenced by cytokine stimula-T
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tion, as it is observed in CB hematopoietic progenitors,
whether unprimed or treated with SCF/Flt3-L, in MPB
CD34  cells, and in CD34  myeloid cell lines, which are
dependent on GM-CSF (TF1) or IL-15 (TF1 , M07sb)
for growth.
IL-15– and GM-CSF–dependent Proliferation in TF1 
Cells Is Modified by Anti–GM-CSFR  and Anti- c mAbs,
Respectively. The presence of the hybrid receptor on
CD34  cells dependent on IL-15 or GM-CSF led us to
investigate the role of this receptor in cell proliferation. As
illustrated in Fig. 2 A, TF1  cells proliferated in the pres-
ence of rIL-15 ( 200%) or rGM-CSF ( 300%). IL-15–
dependent proliferation was inhibited by anti–IL-15R ,
but not by anti- c mAbs. Anti-GM-CSFR  mAb slightly,
but significantly increased ( 20–25%, P   0.001) the rate
of cell proliferation.
In contrast, GM-CSF–dependent proliferation was to-
tally inhibited not only by anti–GM-CSFR  mAb, but also
by anti- c mAb, further suggesting that there is cross talk
between these two cytokine receptors in these cells. As a
control, we used the Raji cell line, the growth of which is
not dependent on IL-15, and which expresses IL-15R 
and  c, but not IL-15R  chains (reference 30; Fig. 2 B).
After 4 d in culture, Raji cells fed with DMEM supple-
mented with 10% FCS proliferated, resulting in a 200% in-
crease in cell density. The addition of 10 ng/ml of rIL-15
increased the proliferation of these cells ( 30%). This ef-
fect was inhibited by anti-IL-15R  mAb, but not by
anti- c or anti-GM-CSFR  mAbs. Anti–IL-15 and anti–
IL-15R mAbs have been shown to have similar effects on
Raji cells (25).
We investigated whether the growth of TF1  cells could
be stimulated by contact with human stromal MS9 cells,
which have been shown to secrete several hematopoietic
growth factors (26), and whether the hybrid receptor was
involved in these interactions. TF1  cells proliferated
when cultured in contact with MS9 cells, doubling in
number after 4 d (Fig. 2 C). The proliferation induced by
MS9 cells was totally inhibited by neutralizing mAbs
against the GM-CSFR  and GM-CSFR  chains. Neutral-
izing mAbs directed against IL-15 or the IL-15R  chain
had no effect whereas anti–IL-15R / c mAbs inhibited
the proliferation of TF1  cells by 60%. Thus, TF1  cell
proliferation is completely dependent on GM-CSF pro-
duced by MS9 cells (26) and can be efficiently inhibited by
anti–IL-15R / c mAbs, consistent with the existence of
cross talk between the two cytokine receptors.
IL-15–induced JAK/STAT Signaling Is Inhibited by Anti–
GM-CSFR  mAb. The inability of the anti- c mAb to
block IL-15–dependent proliferation in TF1  cells suggests
that the  c chain cannot mediate the effects of IL-15 in
these cells. We investigated the signal transduction trig-
gered by IL-15 and the involvement of the various subunits
of the IL-15R, in TF1  cells.
Densitometric analysis revealed that rIL-15 (10 ng/ml)
caused the levels of phosphorylation of JAK1 and STAT3
to increase by a factor of seven within 15 min (Fig. 3 A).
Neutralizing anti–IL-15R  mAb totally inhibited the
phosphorylation of JAK1 and inhibited that of STAT3 by
50%. In contrast, anti- c mAb had no effect on either
pathway. These data confirm the results of the proliferation
assays, demonstrating the incapacity of the  c chain to me-
diate IL-15–dependent functions in TF1  cells.
We then investigated whether the GM-CSFR  chain
interfered with  c chain activity, as suggested by the results
of the proliferation assays. Constitutive levels of JAK1,
JAK2, STAT5, and STAT6 phosphorylation were low in
TF1  cells (Fig. 3 B). Densitometric analysis showed that
rIL-15 (10 ng/ml) induced an increase by a factor of at least
two in the level of phosphorylation of all of these mole-
cules, within 15 min. The phosphorylation of JAK1,
STAT5, and STAT6 was totally inhibited not only by
the synergistic combination of anti–IL-15R  and anti- c
mAbs, but also by neutralizing anti–GM-CSFR  mAb.
In contrast, JAK2 phosphorylation was totally inhibited
by anti–IL-15R / c mAb but was only inhibited by 30%
with the anti-GM-CSFR  mAb. The use of an isotype-
matched anti-gp130 mAb had no significant effect on the
level of phosphorylation of the various molecules. In con-
trast to what was observed in TF1  cells, anti–GM-CS-
FR  mAb did not affect IL-15 signaling in CD34  pro-
megakaryocytic M07sb cells expressing a low-affinity
IL-15R / c receptor (unpublished data).
GM-CSF–induced pSTAT5 Nuclear Translocation Is Inhib-
ited by Anti–IL-15R / c mAbs in TF1  Cells. We ana-
lyzed the effects of anti–IL-15R / c mAbs on the signal
transduction activated by rGM-CSF (Fig. 4 A). Densito-
metric analysis revealed that rGM-CSF (at a concentration
Figure 1.  c/GM-CSFR  interaction in human hematopoietic and nonhematopoietic cells. (A) Western blots of total lysates. MPB CD34  cells,
TF1, and M07Sb promyeloid CD34  cell lines were analyzed for the expression for  c and GM-CSFR  chains. Briefly, cell lysates were subjected to
electrophoresis and the protein bands were transferred to PVDF membranes. The total lysate membranes (Tot.lys) were then probed with anti- c or
anti–GM-CSFR  mAbs. The data shown are representative of three independent experiments. (B) Coimmunoprecipitation MPB CD34  cells, CBPr
CD34 /CD56  and normal polyclonal NK cells (panel a), TF1, TF1 , MO7sb promyeloid CD34 and NK-L cell lines (panel b) and human skin myo-
fibroblasts (panel c) were analyzed for  c/GM-CSFR  interactions. Briefly, total lysates were subjected to immunoprecipitation (IP) with an anti- c an-
tibody. Immunoprecipitates were subjected to electrophoresis and the protein bands were transferred to PVDF membranes. Membranes corresponding to
the  c immunoprecipitate and to total lysates (Tot.lys) were probed with anti- c or anti-GM-CSFR  mAb. The data presented are representative of
three independent experiments. (C) Confocal microscopy. Analysis by confocal microscopy of the interactions between the  c chain (green staining) and
GM-CSFR  (red staining) in MPB CD34  cells (panel a1), CBPr CD34  cells (panel a2), TF1 cells (panel b1), TF1  cells (panel b2), M07Sb (panel b3),
and MS9 spleen myofibroblasts (panel c). As specificity controls, we analyzed the interactions between the  c chain (green staining) and IL-6R gp130
(red staining, panel d) or between the  c chain (green staining) and  1 integrin (red staining, panel e) in CB CD34  cells. The images presented are com-
pacted overlay pictures from serial optical sections, 1  m thick, from the outside to the inner compartments of the cell. The yellow staining indicates
colocalization of the various molecules. The data presented are representative of three independent experiments.T
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of 10 ng/ml) doubled the phosphorylation of JAK2 and
quadrupled that of STAT5 in TF1  cells in a 15-min pe-
riod. In experiments with anti–IL-15R / c mAbs, the
specific JAK3 inhibitor WHI-P31 or the irrelevant anti-
gp130 mAb, we observed no significant inhibition of either
pathway, which demonstrated that neither of the two
chains of the IL-15R affected these steps of GM-CSF sig-
naling. The effects of rGM-CSF and IL-15R / c mAbs
on the localization of pSTAT5 were analyzed by confocal
microscopy (Fig. 4 B). Cells were stained for pSTAT5
(green staining) and with propidium iodide (specific for
nuclei; red staining); superimposition of the two stains gave
a yellow coloration. In basal culture conditions, all cells dis-
played green staining of the cytoplasm, indicating the pres-
ence of pSTAT5 protein in this compartment. The inten-
sity of the green staining increased after GM-CSF
stimulation suggesting that the level of STAT5 phosphory-
lation increased. No inhibition was observed in the pres-
ence of neutralizing anti-IL-15R / c mAbs, or of the specific
JAK3 inhibitor WHI-P31 (unpublished data), confirming
the results obtained by Western blotting.
In basal culture conditions, only a few cells displayed
yellow staining indicating the presence of pSTAT5 in the
nucleus. Control cultures displayed only red nuclear stain-
ing when treated with PI and the second reagent. Short-
term stimulation with rGM-CSF (15 min) induced the
massive nuclear translocation of pSTAT5 in 30% of the
cells, as demonstrated by intense yellow staining of the nu-
cleus. Finally, anti–IL-15R / c mAbs efficiently inhibited
the effects of rGM-CSF on pSTAT5 nuclear translocation,
as shown by a loss of the yellow staining, whereas the iso-
type-matched anti-gp130 mAb had no effect (unpublished
data). The effects on STAT5 of anti-IL-15R / c mAbs
and of the specific JAK3 inhibitor WHI-P31 were also ob-
served in M07Sb cells (unpublished data).
TF1 Cells Express Functional IL-15R / c Complex, the
Formation of which Is Controlled by the Hybrid  c/GM-CS-
FR  Receptor. The absence of proliferation in IL-15R /
 c-positive TF1 cells in response to IL-15 has been attrib-
uted to the lack of the IL-15R  subunit (23), which is in-
dispensable for IL-15 binding and  c chain signaling (7).
However, it has recently been reported that the IL-15R 
chain may transduce a signal in the absence of links with
any other receptor subunit (12), leading to NF- B activa-
tion via the cytoplasmic interaction of this molecule with
the signaling molecule TRAF2. We therefore investigated
the possible presence of a functional IL-15R / c receptor
in TF1 cells. Analysis of total lysates showed that the TF1
Figure 2. Proliferation induced by rIL-15 and rGM-CSF: IL-15R/
GM-CSFR cross talk in TF1  cells. (A) Proliferative response of TF1 
cells to recombinant IL-15 and GM-CSF. TF1  (IL-15R / / c)
CD34  cells were cultured for 4 d with rIL-15 or rGM-CSF (10 ng/ml)
and their proliferation potential was then analyzed. Sister cultures were
continuously incubated with neutralizing mAbs recognizing the IL-15R ,
 c, and GM-CSFR  chains. In TF1  cells cultured with rIL-15, the pro-
liferation rates of samples treated with an anti–GM-CSFR  mAb were
significantly higher ( 25%; P   0.001) than those of samples incubated
with rIL-15 alone or with rIL-15 plus an anti- c mAb. (B) Proliferative
response of Raji cells to rIL-15. Raji cells (IL-15R / c) were cultured
for 4 d with rIL-15 (10 ng/ml) and analyzed for proliferation. Sister cul-
tures were continuously incubated with neutralizing mAbs recognizing
the IL-15R ,  c, and GM-CSFR  chains. (C) Proliferative response of
TF1  cells to MS9 cells. TF1  cells were cocultured for 4 d with MS9
cells and analyzed for proliferation. Sister cultures were continuously in-
cubated with neutralizing mAbs recognizing the GM-CSFR , GM-CSFR ,
IL-15R / c, IL-15R  chains, and IL-15. Cells were counted in an elec-
tronic Coulter counter and the data are expressed as % difference in pro-
liferative potential with respect to control untreated samples. The data
presented are representative of three independent experiments.T
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and TF1  cell lines expressed the  c chain (64 kD) and at
least two IL-15R  isoforms, 58 and 38 kD in size (Fig. 5
A). The two cell lines were then incubated with an anti- c
mAb for immunoprecipitation. The  c membrane was re-
probed with the anti- c mAb. A strong specific signal was
identified at 64 kD. In contrast, two major bands, 58 and
38 kD in size, were identified if the membrane was re-
probed with anti–IL-15R  mAb. Thus, in both TF1 and
TF1  cells, the  c chain is physically associated with the
two IL-15R  isoforms.
Stimulation with rIL-15 induced JAK3 phosphorylation
(increase by a factor of 15) only in the presence of anti–
GM-CSFR  mAb, indicating that the IL-15R / c recep-
tor is potentially functional in TF1 cells (Fig. 5 B). A simi-
lar result was also obtained with TF1  cells.
Total lysates of the TF1 and TF1  cell lines were sub-
jected to immunoprecipitation with an anti-JAK3 mAb,
and the JAK3 membranes were probed with the anti-phos-
photyrosine mAb 4G10. A single phosphorylated band was
detected for the samples treated with an anti-GM-CSFR 
mAb. Reprobing of the membrane with an anti-JAK3 mAb
resulted in the detection of a single protein with migration
characteristics identical to those of the phosphorylated band
detected on the 4G10 Western blot, indicating that the
phosphorylated protein is, indeed, JAK3. These data indi-
cate that the  c subunit of the IL-15R / c receptor is
Figure 3. IL-15 signal transduction: IL-15R/GM-
CSFR cross talk in TF1  cells. Analysis of JAK/STAT sig-
nal transduction by Western blotting. TF1  cells were in-
cubated with 10 ng/ml rIL-15 for 15 min at 37 C. Sister
cultures were pretreated for 1 h with neutralizing anti–IL-
15R / c, anti-GM-CSFR , or anti-IL-6R gp130 mAbs.
Cell extracts were analyzed by Western blotting using anti-
phospho-JAK1 (pJAK1), anti-phospho-JAK2 (pJAK2),
anti-phospho-TYK2 (pTYK2), anti-phospho-STAT5
(pSTAT5), and anti-phospho-STAT6 (pSTAT6) antibod-
ies. Membranes were then reprobed with antibodies rec-
ognizing the native proteins. To correct for possible varia-
tions in the amount of protein loaded, values are expressed
as pJAK/JAK or pSTAT/STAT ratios. pJAK/JAK and
pSTAT/STAT levels were determined by densitometry
including correction for background (NIH Image soft-
ware). Results are expressed as increases (e.g., two times)
with respect to untreated cells. The data presented are rep-
resentative of three independent experiments.T
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functional in TF1 cells, even in the absence of the IL-15R 
chain, but that signaling is controlled by GM-CSFR . The
hybrid receptor is, therefore, functional in these cells.
We analyzed whether the IL-15R / c complex was as-
sociated with the signaling molecule TRAF2 (Fig. 5 C).
Analysis of total lysates with anti-TRAF2, anti- c, or anti–
IL-15R  mAbs showed that TF1 cells expressed TRAF2
(55 kD), the 58 kD IL-15R  isoform and the  c chain (64
kD). After immunoprecipitation with an anti-TRAF2 anti-
body, reprobing of the TRAF2 membranes with mAbs
recognizing the IL-15R  and  c chains resulted in the de-
tection of specific 58 and 64 kD bands, respectively, indi-
cating that TRAF2 is physically associated with the IL-
15R  58 kD standard isoform and the  c chain.
We also showed that rIL-15, but not rIL-7, triggered
phosphorylation of the p65 NF- B subunit inhibitor I B 
Figure 4. GM-CSF signal
transduction: IL-15R/GM-
CSFR cross talk in TF1  cells.
(A) Analysis of JAK2/STAT5
signal transduction by Western
blotting. TF1  cells were incu-
bated with 10 ng/ml rGM-CSF
for 15 min at 37 C. Sister cul-
tures were pretreated for 1 h
with neutralizing anti–IL-15R /
 c mAbs or specific JAK3 inhib-
itors. Cell extracts were analyzed
by Western blotting with anti-
phospho-JAK2 (pJAK2) and
anti-phospho-STAT5 (pSTAT5)
antibodies. Membranes were
then reprobed with antibodies
recognizing the native proteins.
To correct for possible variations
in the amount of protein loaded,
values are expressed as pJAK/
JAK or pSTAT/STAT ratios.
pJAK/JAK and pSTAT/STAT
levels were determined by densi-
tometry, including correction for
background (NIH Image soft-
ware). Results are expressed as
an increase (e.g., two times) with
respect to untreated cells. The
data presented are representative
of three independent experi-
ments. (B) Analysis of pSTAT5
nuclear localization by confocal
microscopy. TF1  cells were in-
cubated with 10 ng/ml rGM-
CSF for 15 min at 37 C. Sister
cultures were pretreated for 1 h
with neutralizing anti-IL-15R /
 c mAbs. Control (basal) and
treated cultures were analyzed by
confocal microscopy for
pSTAT5 distribution in the cell,
focusing particularly on whether
this protein was present in the
nucleus. Propidium iodide stains
nuclei red whereas pSTAT5 is
stained green. Yellow staining
indicates the presence of
pSTAT5 in the nucleus.T
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(42 kD) within 15 min in TF1 and TF1  cells (Fig. 5 D).
Reprobing the membranes with an anti– -actin mAb
identified a band of similar intensity at 42 kD in each sam-
ple, indicating that the gel had been evenly loaded in terms
of amount of protein. We also showed by confocal micros-
copy that rIL-15, but not rIL-7, induced the translocation
to the nucleus of the p65 NF- B subunit (unpublished
data). These data indicate that, in TF1 cells, the IL-15R 
chain is functional and able to activate the NF- B factor.
Moreover, not only does its association with the  c chain
Figure 5. IL-15R / c inter-
action in TF1 and TF1  cells.
(A) Coimmunoprecipitation.
TF1 and TF1  cells were ana-
lyzed for IL-15R / c interac-
tions. Briefly, lysates were sub-
jected to immunoprecipitation
(IP) with an anti- c antibody.
Immunoprecipitates were sub-
jected to electrophoresis and the
protein bands were transferred to
PVDF membranes. Membranes
corresponding to immunoprecip-
itated   c and total lysates
(Tot.lys.) were probed with anti-
 c or anti–IL-15R  mAbs. The
data presented are representative
of three independent experi-
ments. (B) Analysis of JAK3
phosphorylation by Western
blotting. TF1 and TF1  cells
were incubated with 10 ng/ml
rIL-15 for 15 min at 37 C. Sister
cultures were pretreated for 1 h
with neutralizing anti–IL-15R ,
anti–GM-CSFR , and anti-
gp130 mAbs. Cell extracts were
subjected to immunoprecipita-
tion with an anti-JAK3 mAb.
JAK3 membranes were then re-
probed with anti-phosphoty-
rosine 4G10 or anti-JAK3 mAbs.
To correct for possible variations
in the amount of protein loaded,
values are expressed as pJAK3/
JAK3 ratios. pJAK3/JAK3 levels
were determined by densitome-
try, including correction for
background (NIH Image soft-
ware). Results are expressed as
increases (e.g., two times) with
respect to untreated cells. The
data presented are representative
of three independent experi-
ments. (C) Coimmunoprecipita-
tion. TF1 cells were analyzed for
interactions between TRAF2,
IL-15R , and  c. Briefly, lysates
were subjected to immuno-
precipitation (IP) with an anti-
TRAF2 antibody. Immuno-
precipitates were subjected to
electrophoresis and the protein
bands were transferred to PVDF
membranes. Membranes corre-
sponding to immunoprecipitated
TRAF2 and total lysates
(Tot.lys.) were probed with anti-
TRAF2, anti- c, or anti-IL-
15R  mAbs. The data presented are representative of three independent experiments. (D) Analysis of I B  phosphorylation by Western blotting. TF1 and
TF1  cells were incubated with 10 ng/ml rIL-15 or rIL-7 for 15 min at 37 C. Cell extracts were analyzed by Western blotting with anti-phospho-I B 
(pI B ) antibody. Membranes were then reprobed with an antibody recognizing  -actin. To correct for possible variations in the amount of protein
loaded, values are expressed as pI B /  actin ratios. pI B /  actin levels were determined by densitometry, including correction for background (NIH
Image software). Results are expressed as increases with respect to untreated cells. The data presented are representative of three independent experiments.T
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not interfere with NF- B activation, it also probably ren-
ders the  c chain functional even in the absence of the IL-
15R  chain, as shown by the induction of JAK3 phosphor-
ylation by rIL-15.
IL-15–induced STAT5 Signaling Is Inhibited by Anti–GM-
CSFR  mAb in Normal CBPr CD34 /CD56  Cells. Fi-
nally, we investigated the functional significance of the hy-
brid receptor in normal CB hematopoietic progenitors and
the properties of this receptor in these cells. We used pop-
ulations of CB progenitors that had been expanded for 5 d
in the presence of SCF and Flt3-L (CBPr CD34 /CD56 ).
This facilitates proliferation of the hematopoietic progeni-
tors, which maintain a CD34 /CD56  phenotype with no
expression of lineage-specific markers (7). We found that
rIL-15 quadrupled levels of STAT3 phosphorylation,
which was not significantly affected by anti–GM-CSFR 
or isotype-matched control anti-gp130 mAbs (Fig. 6). As
expected, rGM-CSF did not induce STAT3 phosphoryla-
tion. In contrast, anti- c, but not anti-gp130 mAbs in-
hibited constitutive STAT3 phosphorylation, suggesting
interference with an autocrine IL-15–dependent loop. In-
deed, unprimed hematopoietic precursors secrete several
hematopoietic cytokines that regulate normal hematopoie-
sis (3) by autocrine/paracrine loops, and IL-15 belongs to
this group (20).
Both rIL-15 and rGM-CSF induced STAT5 phosphory-
lation (increases by factors of 10 and 7, respectively). Anti–
GM-CSFR  mAb totally abolished the effect of rIL-15
whereas the action of rGM-CSF action was inhibited by
only 35% with an anti- c mAb. No significant inhibition
was observed if an anti-gp130 mAb was used. Finally, CBPr
CD34 /CD56  progenitors displayed discrete constitutive
STAT6 phosphorylation, with an 80% increase in phos-
phorylation in response to rIL-15, but no effect of rGM-
CSF. The various neutralizing mAbs had no significant ef-
fect on STAT6 phosphorylation.
Discussion
We found that human CD34  hematopoietic progeni-
tors express a novel hybrid receptor composed of the  c
chain of IL-2R and the GM-CSFR  chain. This receptor
Figure 6. IL-15 signal trans-
duction: IL-15R/GM-CSFR
cross talk in CBPr CD34 /
CD56  cells. Analysis of STAT
signal transduction by Western
blotting. CB CD34  cell popu-
lations were expanded by incu-
bation for 5 d in the presence of
SCF and Flt3-L. These cells dis-
played a CD34 /CD56  phe-
notype with no expression of
lineage-specific markers. These
CBPr CD34 /CD56  progeni-
tors were incubated with 10 ng/
ml rIL-15 or rGM-CSF for 15
min at 37 C. Sister cultures were
pretreated for 1 h with neutraliz-
ing anti-IL-15R / c, anti-GM-
CSFR , or anti-IL-6R gp130
mAbs. Cell extracts were ana-
lyzed by Western blotting with
anti-phospho-STAT3 (pSTAT3),
anti-phospho-STAT5 (pSTAT5),
and anti-phospho-STAT6
(pSTAT6) antibodies. Mem-
branes were then reprobed with
antibodies recognizing the native
proteins. To correct for possible
variations in the amount of pro-
tein loaded, values are expressed
as pSTAT/STAT ratios. pSTAT/
STAT levels were determined by
densitometry, including correc-
tion for background (NIH Image
software). Results are expressed as
increases with respect to un-
treated cells. The data presented
are representative of two inde-
pendent experiments.T
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was also found in CD34  hematopoietic cell lines with
proerythroid (TF1, TF1 ) or promegakaryocytic (M07sb)
differentiation potentials and in CBPr CD34 /CD56  pre-
cursors, but not in the cytolytic NK-L cell line, normal
NK cells or nonhematopoietic human cells, even though
all these cells produce both chains. The hybrid receptor is
functional and mediates signal transduction by both the IL-
15 and GM-CSF pathways. Indeed, the results obtained
with an anti-GM-CSFR  mAb suggested that, in TF1 
cells, the GM-CSFR  chain replaces the  c chain, inhibit-
ing its specific signaling (phosphorylation of JAK3), but
that this chain cooperates with the IL-15R  chain, facili-
tating the IL-15–dependent activation of other JAK/STAT
pathways (JAK1, JAK2, STAT5, and STAT6) and control-
ling the proliferation of these cells. In contrast, an anti- c
mAb inhibited the GM-CSF–dependent proliferation of
TF1  cells treated with the recombinant cytokine or co-
cultured with human stromal hematopoietic cells secreting
GM-CSF. This suggests that the hybrid receptor may have
important effects in vivo, interfering in the interactions be-
tween CD34  cells and stromal cells that play a major role
in the control of both normal and pathological hemato-
poiesis (1, 2). In addition, anti–IL-15R / c mAbs, and
the specific JAK3 inhibitor WHI-P31, inhibited the nu-
clear translocation of STAT5 induced by rGM-CSF but
did not inhibit the phosphorylation of STAT5. These ef-
fects on STAT5 were also observed in M07Sb cells. Our
observation that the  c subunit of the hybrid receptor con-
trols the GM-CSF–dependent nuclear translocation of
pSTAT5 rather than STAT5 phosphorylation is consistent
with recent results showing that the tyrosine phosphoryla-
tion and nuclear translocation of STAT proteins are regu-
lated independently (31, 32). Indeed, in human kerati-
nocytes, which express a type II IL-4R, IL-4 induces the
phosphorylation of STAT3, but not its nuclear transloca-
tion (31), whereas the prolactin receptor (PRLR) regulates
STAT5 tyrosine phosphorylation and nuclear translocation
by means of two independent pathways (32). With PRLR,
the number of phosphorylated tyrosines on the receptor it-
self seems to play a critical role in the activation of a cellu-
lar component that controls the number of STAT5 com-
plexes in the cytoplasm, by controlling the entry of these
complexes into the nucleus (32). Moreover, STAT5 tyro-
sine phosphorylation and DNA binding via the IL-2R 
chain requires receptor phosphotyrosines (33), whereas
similar events mediated by the G-CSFR are independent
of receptor phosphotyrosines (34). Thus, the structural or-
ganization of some receptors and the subsequent activation
of particular signaling pathways may affect the transloca-
tion of STAT protein to the nucleus.
On the basis of these results, we propose a model for the
activation of STAT5 by rGM-CSF via the hybrid receptor
 c/GM-CSFR . We suggest that STAT5 tyrosine phos-
phorylation and nuclear translocation are regulated inde-
pendently and that the translocation pathway is controlled
by the  c/JAK3 complex, which, in cells with type I IL-
4R, is necessary for the translocation of STAT5 to the nu-
cleus (35).
The hybrid receptor is functional not only in leukemic
cell precursors, but also in normal progenitors, although its
functions appear more limited in normal cells. Indeed, in
normal CBPr CD34 /CD56  progenitors, the hybrid re-
ceptor controls the IL-15–dependent phosphorylation of
STAT5 but not of STAT3 and STAT6. Moreover, levels
of GM-CSF–dependent STAT5 phosphorylation are de-
creased by anti- c mAb in CBPr CD34 /CD56  progeni-
tors, but not in TF1  cells. These differences may be due
to differences in origin (normal versus pathological) and/or
degree of primitiveness of the two types of CD34  cell. In
any case, our results emphasize the involvement of the hy-
brid receptor in the control of normal and pathological he-
matopoiesis, with this receptor probably displaying various
functions during hematopoietic development.
The absence of the hybrid receptor on nonhematopoi-
etic cells strengthens the evidence for its “specific” involve-
ment in hematopoiesis. The distribution of this receptor in
cells of various lineages and functions suggests that it is in-
volved in the development of hematopoiesis, probably af-
fecting engagement in myeloid, rather than lymphoid, lin-
eages. Indeed, the inhibition of  c/JAK3 signaling by the
GM-CSFR  chain should be interpreted in light of the in-
hibition of lymphocyte maturation and myelopoiesis dys-
regulation observed in mice and humans bearing  c or
JAK3 deletions or mutations (9–11).
In erythrocytic TF1 cells, we describe, for the first time,
a novel IL-15R / c/TRAF2 complex that triggers spe-
cific IL-15 signaling, even though these cells do not express
the IL-15R  chain23, a subunit indispensable for the  c
chain functions (7). Both subunits of the IL-15R / c het-
erodimer are functional, although they behave differently
from what would be expected based on the results obtained
for other cell types. It has been reported that IL-15R , as-
sociating with the signaling molecule TRAF2, activates the
transcription factor NF- B, in the absence of a link with
the  c chain (12, 24). In contrast, in TF1 cells, IL-15R 
and   c are associated but we nevertheless observed the
phosphorylation, not only of I B , but also of JAK3 fac-
tors. However, the phosphorylation of JAK3 factor was
only observed in samples treated with rIL-15 and anti–
GM-CSFR  mAb, indicating that the  c/JAK3 pathway is
functional in the absence of the IL-15R  chain but is con-
trolled by the hybrid receptor.
The association of IL-15R / c/TRAF2 may play a reg-
ulatory role at certain stages of hematopoiesis, associating
NF- B activation, which is involved in the control of
erythropoiesis (15), with the conditional activation of
JAK3-dependent pathways.
Finally, we showed that rIL-15 induced the phosphory-
lation of STAT6 both in leukemic TF1  proerythroid pre-
cursors, and in normal CBPr CD34 /CD56  progenitors.
Our data suggest that this unusual IL-15–dependent path-
way, the activation of which in mast cells was attributed to
the high-affinity p65 IL-15RX receptor (28, 29), is also
triggered in other types of CD34  precursor. However, in
TF1  cells, this pathway is controlled by the classical IL-
15R / / c receptor and/or by the  c/GM-CSFR  hy-T
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brid receptor, whereas in normal CBPr, CD34 /CD56 
IL-15–dependent STAT6 phosphorylation is not con-
trolled by the hybrid receptor. Overall, these results suggest
the possible and complex involvement of STAT6 in the
control of hematopoiesis (36) and provide further evidence
that IL-15/GM-CSF are involved in cross talk.
Recent data have shown that unprimed hematopoietic
progenitors secrete several mediators activating autocrine/
paracrine regulatory loops (3). For instance, CD34  cells
may express GM-CSF transcripts (3) and a biologically ac-
tive IL-15 that controls expression of the  c chain, but is
not competent for inducing the spontaneous differentiation
of these cells into NK cells (20). Thus, IL-15 and GM-CSF
may contribute, by means of the hybrid receptor, to the
autocrine/paracrine cross talk that controls the develop-
ment of hematopoietic cells (3), perhaps by inhibiting the
spontaneous engagement of these cells in the lymphoid lin-
eage. In contrast, in leukemic hematopoiesis, the action of
the hybrid receptor is probably irreversible and may be in-
volved in the molecular mechanisms responsible for the in-
hibition of differentiation in certain leukemic clones.
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